Cardax, Inc. (CDXI)
OTCQB OTCQB Primary Summary
Cardax, Inc. (CDXI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cardax, Inc. ever had a stock split?
Cardax, Inc. Profile
| Biotechnology Industry | Healthcare Sector | David G. Watumull CEO | OTCQB Exchange | 14141D201 CUSIP |
| US Country | 10 Employees | - Last Dividend | 15 Jan 2020 Last Split | - IPO Date |
Overview
Cardax, Inc. is a biopharmaceutical company rooted in the development and commercialization of innovative products aimed at combating chronic diseases driven by inflammation and oxidative stress. Situated in Honolulu, Hawaii, its strategic focus lies in the creation of dietary supplements and pharmaceuticals that address critical issues related to inflammatory health. The company leverages advanced scientific research to formulate solutions that promote health and longevity. Via a combination of direct e-commerce and wholesale channels, Cardax ensures the accessibility of its offerings to a broad audience, emphasizing a commitment to improving public health through science-backed products.
Products and Services
- ZanthoSyn
- CDX-101
- CDX-301
An advanced dietary supplement designed for inflammatory health and longevity. ZanthoSyn is unique in its formulation, offering astaxanthin with enhanced absorption and purity to maximize its benefits. This supplement is primarily distributed through e-commerce platforms and wholesale channels, catering to individuals seeking a scientifically supported method to manage inflammation and support overall well-being.
A pharmaceutical candidate under development, CDX-101 represents Cardax's effort to tackle cardiovascular inflammation and dyslipidemia. This astaxanthin-based medication is specifically aimed at addressing severe hypertriglyceridemia, highlighting the company's commitment to addressing heart health through innovative inflammation management strategies. CDX-101 exemplifies the potential of natural compounds in pharmaceutical applications, particularly in combating conditions related to chronic inflammation.
Another promising venture by Cardax into the realm of pharmaceuticals is represented by CDX-301. This zeaxanthin pharmaceutical candidate is being developed with a focus on macular degeneration, a leading cause of vision loss. By targeting the underlying inflammation and oxidative stress associated with this condition, CDX-301 stands as a testament to Cardax's dedication to leveraging scientific advancements to improve life quality through better health outcomes.
